98 related articles for article (PubMed ID: 2402742)
61. Functional activity of protein S determined with use of protein C activated by venom activator.
Kobayashi I; Amemiya N; Endo T; Okuyama K; Tamura K; Kume S
Clin Chem; 1989 Aug; 35(8):1644-8. PubMed ID: 2527095
[TBL] [Abstract][Full Text] [Related]
62. Interlaboratory evaluation of methods for the assay of Protein C in purified concentrates.
Regnault V; Droulle C; Houbouyan L; Michalski C; Vergnes C; Briquel ME; Delattre H; Potron G; Boisseau M; Alexandre P
J Int Fed Clin Chem; 1993 Jul; 5(3):106-11. PubMed ID: 10146222
[TBL] [Abstract][Full Text] [Related]
63. Enzyme enhancement for the measurement of protein C.
Han P; Nathan IV
Clin Lab Haematol; 1987; 9(4):409-13. PubMed ID: 3327647
[TBL] [Abstract][Full Text] [Related]
64. PROTAC moves in on lymphoma.
Cully M
Nat Rev Drug Discov; 2019 Jul; 18(8):584. PubMed ID: 31367054
[No Abstract] [Full Text] [Related]
65. PROTAC Degradation of IRAK4 for the Treatment of Neurodegenerative and Cardiovascular Diseases.
Kargbo RB
ACS Med Chem Lett; 2019 Sep; 10(9):1251-1252. PubMed ID: 31531192
[No Abstract] [Full Text] [Related]
66. Treatment of Cancer and Alzheimer's Disease by PROTAC Degradation of EGFR.
Kargbo RB
ACS Med Chem Lett; 2019 Aug; 10(8):1098-1099. PubMed ID: 31413790
[No Abstract] [Full Text] [Related]
67. PROTAC Molecules for the Treatment of Autoimmune Disorders.
Kargbo RB
ACS Med Chem Lett; 2019 Mar; 10(3):276-277. PubMed ID: 30891126
[No Abstract] [Full Text] [Related]
68. PROTAC Degradation of Bromodomain for the Treatment of Hyperplasia and Cancer.
Kargbo RB
ACS Med Chem Lett; 2019 Oct; 10(10):1372-1373. PubMed ID: 31620218
[No Abstract] [Full Text] [Related]
69. PROTAC Degradation of IRAK4 for the Treatment of Cancer.
Kargbo RB
ACS Med Chem Lett; 2019 Oct; 10(10):1370-1371. PubMed ID: 31620217
[No Abstract] [Full Text] [Related]
70. PROTAC-Mediated Degradation of Estrogen Receptor in the Treatment of Cancer.
Kargbo RB
ACS Med Chem Lett; 2019 Oct; 10(10):1367-1369. PubMed ID: 31620216
[No Abstract] [Full Text] [Related]
71. PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics.
Kargbo RB
ACS Med Chem Lett; 2020 Jun; 11(6):1090-1091. PubMed ID: 32550985
[No Abstract] [Full Text] [Related]
72. Degrading proteins in animals: "PROTAC"tion goes in vivo.
Guo J; Liu J; Wei W
Cell Res; 2019 Mar; 29(3):179-180. PubMed ID: 30770868
[No Abstract] [Full Text] [Related]
73. FRANCIS C. PHILLIPS.
Silverman A
Science; 1920 May; 51(1323):455-6. PubMed ID: 17837432
[No Abstract] [Full Text] [Related]
74. A Deficient Diagnosis.
Burke AE; Chang L; Cheung A; Ling E; Solomon CG; Williams S
N Engl J Med; 2023 Nov; 389(22):e47. PubMed ID: 38048187
[No Abstract] [Full Text] [Related]
75. Protein C Thr315Ala variant results in gain of function but manifests as type II deficiency in diagnostic assays.
Ding Q; Yang L; Dinarvand P; Wang X; Rezaie AR
Blood; 2015 Apr; 125(15):2428-34. PubMed ID: 25651845
[TBL] [Abstract][Full Text] [Related]
76. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate.
Müller FM; Ehrenthal W; Hafner G; Schranz D
Eur J Pediatr; 1996 Jan; 155(1):20-5. PubMed ID: 8750805
[TBL] [Abstract][Full Text] [Related]
77. Symptomatic hereditary type-II protein C deficiency caused by a missense mutation in exon IX of the protein C gene (Gly381 to Ser).
Wittmann E; Walter J; Pabinger-Fasching I; Watzke HH
Ann Hematol; 1994 May; 68(5):255-9. PubMed ID: 8018768
[TBL] [Abstract][Full Text] [Related]
78. Diagnosis of protein C deficiency in patients on oral anticoagulant treatment: comparison of three different functional protein C assays.
Pabinger I; Kyrle PA; Speiser W; Stoffels U; Jung M; Lechner K
Thromb Haemost; 1990 Jun; 63(3):407-12. PubMed ID: 2402742
[TBL] [Abstract][Full Text] [Related]
79. [Study of chromogenic substrate on protein C activity assay--in patients treated with warfarin].
Sakata T; Hatsuyama H; Kitamura T; Uchida K; Katayama Y; Matsuyama T
Rinsho Byori; 1990 Aug; 38(8):937-41. PubMed ID: 2232257
[TBL] [Abstract][Full Text] [Related]
80. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
Johnstone IB; Martin CA
Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
